Big things are being tipped for biotechnology company Prima Biomed . The stock has surged more than 175 per cent over the past 12 months. Just this year, during which the company has raised $60 million in new equity, it has risen more than 70 per cent. The company, which has borne comparisons to multibillion-dollar US-listed Dendreon, is focused on treatments for ovarian and cervical cancer. It’s main product, CVac, a treatment for ovarian cancer, received its first approval last month from regulatory authorities in Dubai. Southern Cross Equities has a buy rating and 75¢ target price.